ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023

02 May 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

01 May 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

25 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

10 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia

30 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics

09 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

07 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

02 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023

31 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

14 Dec 2022 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

12 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

02 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

01 Dec 2022 19:26:21 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

28 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

23 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022

08 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

07 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022

17 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy

21 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease

23 Aug 2022 06:00:00 By Nasdaq GlobeNewswire